- Impact of COVID-19 on gynecologic cancer treatment in Japan: a nationwide survey by the Japan Society of Gynecologic Oncology (JSGO)
-
Nogami Y, Komatsu H, Makabe T, Hasegawa Y, Yokoyama Y, Kawana K, Okamoto A, Mikami M, Katabuchi H, The COVID-19 Task Force of the Japan Society of Gynecologic Oncology
- KMID: 2536014
- J Gynecol Oncol.
- 2022 Jan;33(1):e8.
- doi: 10.3802/jgo.2022.33.e8
Objective As coronavirus disease 2019 (COVID-19) rages on, it is a challenging task to balance resources for treatment of COVID-19 and malignancy-based treatment. For the development of optimal strategies, assessing the... -
- CITED
-
- Close
- SHARE
-
- Close
- Prognostication of early-onset endometrioid endometrial cancer based on genome-wide DNA methylation profiles
-
Hirano T, Arai E, Fujimoto M, Nakayama Y, Tian Y, Ito N, Makabe T, Yamagami W, Susumu N, Aoki D, Kanai Y
- KMID: 2537965
- J Gynecol Oncol.
- 2022 Nov;33(6):e74.
- doi: 10.3802/jgo.2022.33.e74
Objective The aim of this study was to establish criteria that would indicate whether fertility preservation therapy would likely be safe for patients aged 40 years or less with endometrioid endometrial... -
- CITED
-
- Close
- SHARE
-
- Close
- Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
-
Yamagami W, Susumu N, Makabe T, Sakai K, Nomura H, Kataoka F, Hirasawa A, Banno K, Aoki D
- KMID: 2404016
- J Gynecol Oncol.
- 2018 Mar;29(2):e21.
- doi: 10.3802/jgo.2018.29.e21
OBJECTIVE: Reports on the repeated administration of medroxyprogesterone acetate (MPA) for intrauterine recurrence after fertility-preserving therapy for atypical endometrial hyperplasia (AEH) and early grade 1 endometrioid carcinoma (G1) are lacking.... -
- CITED
-
- Close
- SHARE
-
- Close
